about
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAITThe effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trialEarly-onset stroke and vasculopathy associated with mutations in ADA2Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood.Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-coSecondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis.Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions.Laser Wavelength Dependence of Background Fluorescence in Raman Spectroscopic Analysis of Synovial Fluid from Symptomatic Joints.Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosusPreliminary criteria for global flares in childhood-onset systemic lupus erythematosusRemittive agents in pediatric rheumatology.Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology.Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus.Development of a Functional Biomarker for Use in Cell-Based Therapy Studies in Seropositive Rheumatoid ArthritisSjögren's syndrome in childhood.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.Mesenchymal stem cells: mechanisms of inflammation.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.Tocilizumab in pediatric rheumatology: the clinical experience.Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus.Critical care myopathy in a child.Mouse CD6: sequence of cDNA and expression of mRNA.Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric mNeutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritisRasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutationsCD166 Expression, Characterization, and Localization in Salivary Epithelium: Implications for Function During SialoadenitisResponsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytesStructures on the cell surface. Update from the fifth international workshop on human leukocyte differentiation antigensEvidence for the expression of a second CD6 ligand by synovial fibroblasts
P50
Q24602794-146D7BFF-80C6-4AF8-8BD7-99F1DCE5F5AAQ24630475-6BCD20E7-EAB2-442D-9179-C07D86EA7758Q30410263-2DDB4D16-A057-4A1C-A9F8-1A134C21260DQ33514010-97005831-0635-4CE0-9E16-833DACB323CFQ33516938-FFC24CD9-D836-4688-8E18-BAED23336964Q33922922-15C6AC51-4B27-475F-B514-68CF9DAAB0FDQ34270161-0B825E8A-259A-4656-9206-DB8AA094AD13Q34363915-80E9B266-7CDF-44F6-84E1-F850FA94AE4FQ34994103-C72495FF-C9EE-491C-AD20-ABB2D0A8C611Q35007931-0CDADCAC-C0DA-4DCB-829A-38EDA96DE4E6Q35199345-79D75A00-F341-41DE-A499-5C855E3A2171Q35864706-36049867-EA19-4D73-B106-8A7E7499A3DFQ36085018-CF661152-184F-45D8-A17D-7CBBD4776121Q36462746-29EF58D8-5D52-449D-ACD7-ADF625F13F03Q36484106-653D15A7-1ABD-4CC2-8B1D-FC6F74A8655AQ36808606-BF53BE0B-9BD9-4907-BFE5-50812B08DA4AQ37155931-FA7A351E-F11B-42F5-A5D4-A4121171D383Q37331061-B350F672-0A28-426C-B5B9-BD8D9038E865Q37649029-7DAEE310-4BA8-4226-B1BB-61C501F77A71Q37809081-F572E5A0-9368-4431-B0A6-2C26A483DCCEQ37845564-54DF5300-EE1A-4C25-8B09-E478481455D3Q37998319-578474D6-8B78-4FB8-A93B-98C389F5AFE5Q38076917-E3451B35-3F0D-4B52-951A-96DF023D7C3CQ38093452-555C06C2-42CB-4C1C-AC52-C294555CFB46Q38110210-FEBDD7B1-302D-4AA2-B104-78FF09DCD7F8Q42632072-189A5860-D1FF-42D4-ACBA-D61197334DA7Q46374758-B01D80C9-A91F-4078-AF71-61584F982958Q46853568-7100B2CE-91D3-4438-B42E-9FB6F0E60917Q48067219-7E2DF298-80DB-45D1-9CA6-EBED3FEB0F55Q57751929-3D7ED345-6376-46BA-809E-B278747AD8F5Q60975297-64B1D8A2-34EE-4FCA-B52E-9BD15A75D37FQ60975326-214E48CD-C475-45E1-9C32-CF9D62A66184Q60975334-536B5A45-FE94-4740-AAAA-7708382D66B2Q60975392-1ABA3AA3-BC46-43D6-AF70-3AF942262A4DQ60975398-790927A7-CCBE-4955-ADE0-73799939959FQ73490969-447EB155-D07B-4E0B-B2FA-8716D8C7DCCB
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nora G Singer
@nl
Nora G Singer
@sl
Nora G. Singer
@en
Nora G. Singer
@es
type
label
Nora G Singer
@nl
Nora G Singer
@sl
Nora G. Singer
@en
Nora G. Singer
@es
prefLabel
Nora G Singer
@nl
Nora G Singer
@sl
Nora G. Singer
@en
Nora G. Singer
@es
P106
P1153
7007064894
P21
P31
P496
0000-0001-7041-723X